Commentary: Neoadjuvant checkpoint inhibitors in resectable non–small cell lung cancer—Ready for prime time?

Abstract

Central MessageResults from completed and ongoing neoadjuvant immunotherapy trials in lung cancer suggest that immunotherapy in preoperative setting is safe, feasible, and possibly more effective than chemotherapy alone, as determined by pathologic response rates.

Commentary: Immune cell infiltration in aortic stenosis: Cause or consequence?

“…There has been a great deal of interest in the role of PDL-1 in oncology in recent years. 3 , 4 The expression of PDL-1 in tumor cells acts on PD-1 receptors on cytotoxic T cells, resulting in dysfunction of these cytotoxic T cells. Thus, PDL-1 expression appears to enhance immune system evasion by tumor cells.…”

“…Recently, the PD-1 receptor and PDL-1 have become important therapeutic targets, and monoclonal antibodies directed at these targets have shown impressive efficacy in treating advanced non–small cell lung cancer. 3 , 4 It is interesting to reconcile our understanding of PDL-1 in malignancy with its potential role in calcific aortic stenosis. In malignancy, expression of PDL-1 acts to decrease the immune response and allow cancer cells to evade immune system.…”